6-K 1 form_6-k.htm FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR NOVEMBER, 2023

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the Month of November, 2023

 

Commission File Number: 001-41174

 

RELIEF THERAPEUTICS Holding SA

(Exact name of Registrant as specified in its charter)

 

Not Applicable

(Translation of registrant’s name into English)

 

Switzerland

(Jurisdiction of incorporation or organization)

 

Avenue de Sécheron 15

1202 Geneva

Switzerland

Tel: +41 22 545 11 16

(Address of principal executive offices)

 

Indicate by check mark if the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F     ☒                  Form 40-F     ☐

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1)     ☐

 

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7)     ☐

 


 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On November 22, 2023, Relief Therapeutics Holding SA (the “Company”) announced that its current Chief Executive Officer, Jack Weinstein, will be stepping down as part of a leadership transition, and that Michelle Lock, a highly experienced pharmaceutical executive and current independent member of the Company’s Board of Directors, will be assuming the role of CEO on an interim basis. On the same date, the Company issued a press release reporting the transition entitled “Relief Therapeutics Announces CEO Transition”. A copy of the press release is attached to this Form 6-K as Exhibit 99.1.

 

 

INDEX TO EXHIBITS

 

Exhibit No.   Description
     
99.1   Press Release dated November 22, 2023.

 

- 2 -


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

RELIEF THERAPEUTICS Holding SA

 

By: /s/ Jeremy Meinen

Jeremy Meinen

Chief Financial Officer

 

Dated: November 22, 2023

 

- 3 -